CST Guide:

30
Section IV: Additional Information
Through their ongoing
commitment to innovative
research, CST scientists
have contributed to a
wealth of peer-reviewed
publications in cancer
research, proteomicsbased
discovery, and
novel antibody technology.
2014
Gray, V.E. et al. (2014) Signatures of natural selection
on mutations of residues with multiple posttranslational
modifications. Mol. Biol. Evol. 31, 1641–1645.
Oslund, R.C. et al. (2014) A Phosphohistidine
Proteomics Strategy Based on Elucidation of a Unique
Gas-phase Phosphopeptide Fragmentation Mechanism.
J. Am. Chem. Soc. [Epub ahead of print].
Mulherkar, S. et al. (2014) The small GTPases RhoA
and Rac1 regulate cerebellar development by controlling
cell morphogenesis, migration and foliation. Dev.
Biol. [Epub ahead of print].
2013
Miller, R.A. et al. (2013) Biguanides suppress hepatic
glucagon signalling by decreasing production of cyclic
AMP. Nature 494, 256–260.
Ling, H. et al. (2013) Transforming growth factor β
neutralization ameliorates pre-existing hepatic fibrosis
and reduces cholangiocarcinoma in thioacetamidetreated
rats. PLoS ONE 8, e54499.
Mulherkar, S. et al. (2013) The Small GTPase RhoA Is
Required for Proper Locomotor Circuit Assembly. PLoS
ONE 8, e67015.
Israelsen, W.J. et al. (2013) PKM2 Isoform-Specific
Deletion Reveals a Differential Requirement for Pyruvate
Kinase in Tumor Cells. Cell 155, 397–409.
Hitosugi, T. et al. (2013) Tyr26 phosphorylation of
PGAM1 provides a metabolic advantage to tumours
by stabilizing the active conformation. Nat. Commun.
4, 1790.
Morandell, S. et al. (2013) A Reversible Gene-Targeting
Strategy Identifies Synthetic Lethal Interactions
between MK2 and p53 in the DNA Damage Response
In Vivo. Cell Rep. 5, 868–877.
2012
Hornbeck, P.V. et al. (2012) PhosphoSitePlus: a
comprehensive resource for investigating the structure
and function of experimentally determined posttranslational
modifications in man and mouse. Nucleic
Acids Res. 40, 261–270.
Katayama, R. et al. (2012) Mechanisms of acquired
crizotinib resistance in ALK-rearranged lung Cancers.
Sci. Transl. Med. 4, 120ra17.
Feng, H. et al. (2012) Phosphorylation of dedicator
of cytokinesis 1 (Dock180) at tyrosine residue
Y722 by Src family kinases mediates EGFRvIII-driven
glioblastoma tumorigenesis. Proc. Natl. Acad. Sci. USA
109, 3018–3023.
Garnett, M.J. et al. (2012) Systematic identification of
genomic markers of drug sensitivity in cancer cells.
Nature 483, 570–575.
Cheung, W.C. et al. (2012) A proteomics approach for
the identification and cloning of monoclonal antibodies
from serum. Nat. Biotechnol. 30, 447–452.
290 For Research Use Only. Not For Use in Diagnostic Procedures.
Publications
by CST Scientists
Stokes, M.P. et al. (2012) PTMScan direct: identification
and quantification of peptides from critical signaling
proteins by immunoaffinity enrichment coupled
with LC-MS/MS. Mol. Cell Proteomics 11, 187–201.
Ren, H. et al. (2012) Identification of anaplastic
lymphoma kinase as a potential therapeutic target in
ovarian cancer. Cancer Res. 72, 3312–3323.
Rimkunas, V.M. et al. (2012) Analysis of Receptor
Tyrosine Kinase ROS1-Positive Tumors in Non-Small
Cell Lung Cancer: Identification of a FIG-ROS1 Fusion.
Clin. Cancer Res. 18, 4449–4457.
Xu, W. et al. (2012) Dynamic tyrosine phosphorylation
modulates cycling of the HSP90-P50(CDC37)-AHA1
chaperone machine. Mol. Cell 47, 434–443.
Hardee, M.E. et al. (2012) Resistance of glioblastomainitiating
cells to radiation mediated by the tumor
microenvironment can be abolished by inhibiting transforming
growth factor-β. Cancer Res. 72, 4119–4129.
Hezel, A.F. et al. (2012) TGF-β and αvβ6 integrin act
in a common pathway to suppress pancreatic cancer
progression. Cancer Res. 72, 4840–4845.
Hitosugi, T. et al. (2012) Phosphoglycerate mutase 1
coordinates glycolysis and biosynthesis to promote
tumor growth. Cancer Cell 22, 585–600.
Sato, S. et al. (2012) Proteomics-directed cloning of
circulating antiviral human monoclonal antibodies.
Nat. Biotechnol. 30, 1039–1043.
Buckley, S.M. et al. (2012) Regulation of pluripotency
and cellular reprogramming by the ubiquitin-proteasome
system. Cell Stem Cell 11, 783–798.
Stokes, M.P. et al. (2012) Quantitative Profiling of DNA
Damage and Apoptotic Pathways in UV Damaged Cells
Using PTMScan Direct. Int J. Mol. Sci. 14, 286–307.
Foulkes-Murzycki, J.E. et al. (2012) Cooperative Effects
of Drug-Resistance Mutations in the Flap Region
of HIV-1 Protease. ACS Chem. Biol. 8, 513–518.
Li, Z. et al. (2012) Gr-1+CD11b+ cells are responsible
for tumor promoting effect of TGF-β in breast cancer
progression. Int. J. Cancer 131, 2584–2595.
2011
Hülper, P. et al. (2011) Tumor localization of an
anti-TGF-β antibody and its effects on gliomas.
Int. J. Oncol. 38, 51–59.
Gu, T.L. et al. (2011) Survey of tyrosine kinase signaling
reveals ROS kinase fusions in human cholangiocarcinoma.
PLoS ONE 6, e15640.
Kettenbach, A.N. et al. (2011) Absolute quantification
of protein and post-translational modification abundance
with stable isotope-labeled synthetic peptides.
Nat. Protoc. 6, 175–186.
Verstraeten, V.L. et al. (2011) Protein farnesylation
inhibitors cause donut-shaped cell nuclei attributable
to a centrosome separation defect. Proc. Natl. Acad.
Sci. USA 108, 4997–5002.
Dammer, E.B. et al. (2011) Polyubiquitin linkage
profiles in three models of proteolytic stress suggest
the etiology of Alzheimer disease. J. Biol. Chem. 286,
10457–10465.
Brave, S.R. et al. (2011) Assessing the activity of cediranib,
a VEGFR-2/3 tyrosine kinase inhibitor, against
VEGFR-1 and members of the structurally related
PDGFR family. Mol. Cancer Ther. 10, 861–873.
Pighi, C. et al. (2011) Phospho-proteomic analysis of
mantle cell lymphoma cells suggests a pro-survival
role of B-cell receptor signaling. Cell. Oncol. (Dordr)
34, 141–153.
Gu, T.L. et al. (2011) Survey of activated FLT3
signaling in leukemia. PLoS ONE 6, e19169.
Yadav, H. et al. (2011) Protection from obesity and
diabetes by blockade of TGF-β/Smad3 signaling.
Cell Metab. 14, 67–79.
Kremer, K.N. et al. (2011) Stromal Cell-Derived
Factor-1 Signaling via the CXCR4-TCR Heterodimer
Requires Phospholipase C-{beta}3 and Phospholipase
C-{gamma}1 for Distinct Cellular Responses.
J. Immunol. 187, 1440–1447.
Zhang, Q. et al. (2011) TGF-β regulates DNA methyltransferase
expression in prostate cancer, correlates
with aggressive capabilities, and predicts disease
recurrence. PLoS ONE 6, e25168.
Kim, W. et al. (2011) Systematic and quantitative
assessment of the ubiquitin-modified proteome.
Mol. Cell 44, 325–340.
Emanuele, M.J. et al. (2011) Global Identification of
Modular Cullin-RING Ligase Substrates. Cell 147,
459–474.
Feng, H. et al. (2011) Activation of Rac1 by Src-dependent
phosphorylation of Dock180Y1811 mediates
PDGFRα-stimulated glioma tumorigenesis in mice and
humans. J. Clin. Invest. 121, 4670–4684.
Biswas, S. et al. (2011) Anti-transforming growth
factor ß antibody treatment rescues bone loss and
prevents breast cancer metastasis to bone. PLoS ONE
6, e27090.
Bouquet, F. et al. (2011) TGFβ1 inhibition increases
the radiosensitivity of breast cancer cells in vitro and
promotes tumor control by radiation in vivo. Clin.
Cancer Res. 17, 6754–6765.
Fan, J. et al. (2011) Tyrosine Phosphorylation of
Lactate Dehydrogenase A Is Important for NADH/
NAD+ Redox Homeostasis in Cancer Cells. Mol. Cell.
Biol. 31, 4938–4950.
Hitosugi, T. et al. (2011) Tyrosine phosphorylation
of mitochondrial pyruvate dehydrogenase kinase 1
is important for cancer metabolism. Mol. Cell 44,
864–877.
Lee, K.A. et al. (2011) Ubiquitin ligase substrate
identification through quantitative proteomics at both
the protein and peptide levels. J. Biol. Chem. 286,
41530–41538.
Lonning, S. et al. (2011) Antibody targeting of TGF-β
in cancer patients. Curr. Pharm. Biotechnol. 12,
2176–2189.
2010
Moritz, A. et al. (2010) Akt-RSK-S6 kinase signaling
networks activated by oncogenic receptor tyrosine
kinases. Sci. Signal. 3, ra64.
van Vugt, M.A. et al. (2010) A mitotic phosphorylation
feedback network connects Cdk1, Plk1, 53BP1, and
Chk2 to inactivate the G(2)/M DNA damage checkpoint.
PLoS Biol. 8, e1000287.
Gu, T.L. et al. (2010) Identification of activated
Tnk1 kinase in Hodgkin’s lymphoma. Leukemia 24,
861–865.
Pecquet, C. et al. (2010) Induction of myeloproliferative
disorder and myelofibrosis by thrombopoietin receptor
W515 mutants is mediated by cytosolic tyrosine 112
of the receptor. Blood 115, 1037–1048.
Nishimura, E.K. et al. (2010) Key roles for transforming
growth factor beta in melanocyte stem cell maintenance.
Cell Stem Cell 6, 130–140.
Hudon, V. et al. (2010) Renal tumour suppressor
function of the Birt-Hogg-Dubé syndrome gene
product folliculin. J. Med. Genet. 47, 182–189.
Hirschey, M.D. et al. (2010) SIRT3 regulates mitochondrial
fatty-acid oxidation by reversible enzyme
deacetylation. Nature 464, 121–125.
Schoeberl, B. et al. (2010) An ErbB3 antibody,
MM-121, is active in cancers with ligand-dependent
activation. Cancer Res. 70, 2485–2494.
Ghosh, R. et al. (2010) Phellodendron amurense
bark extract prevents progression of prostate tumors
in transgenic adenocarcinoma of mouse prostate:
potential for prostate cancer management. Anticancer
Res. 30, 857–865.
Kang, S. et al. (2010) p90 ribosomal S6 kinase 2
promotes invasion and metastasis of human head and
neck squamous cell carcinoma cells. J. Clin. Invest.
120, 1165–1177.
Ganapathy, V. et al. (2010) Targeting the Transforming
Growth Factor-beta pathway inhibits human basal-like
breast cancer metastasis. Mol. Cancer 9, 122.
Takaku, S. et al. (2010) Blockade of TGF-beta
enhances tumor vaccine efficacy mediated by CD8(+)
T cells. Int. J. Cancer 126, 1666–1674.
Bonnette, P.C. et al. (2010) Phosphoproteomic characterization
of PYK2 signaling pathways involved in
osteogenesis. J. Proteomics 73, 1306–1320.
Aguiar, M. et al. (2010) Gas-Phase Rearrangements
Do Not Affect Site Localization Reliability in
Phosphoproteomics Data Sets. J. Proteome Res. 9,
3103–3107.
Carretero, J. et al. (2010) Integrative genomic and
proteomic analyses identify targets for Lkb1-deficient
metastatic lung tumors. Cancer Cell 17, 547–559.
Andersen, J.N. et al. (2010) Pathway-based identification
of biomarkers for targeted therapeutics: personalized
oncology with PI3K pathway inhibitors. Sci. Transl.
Med. 2, 43ra55.
Buel, G.R. et al. (2010) Fyn promotes phosphorylation
of collapsin response mediator protein 1 at tyrosine
504, a novel, isoform-specific regulatory site. J. Cell
Biochem. 111, 20–28.
Knowlton, M.L. et al. (2010) Profiling Y561-dependent
and -independent substrates of CSF-1R in epithelial
cells. PLoS ONE 5, e13587.
Edwards, J.R. et al. (2010) Inhibition of TGF-β
signaling by 1D11 antibody treatment increases bone
mass and quality in vivo. J. Bone Miner. Res. 25,
2419–2426.
chapter 30: publications by cst scientists
www.cellsignal.com/cstpubs 291